Drug intelligence / Profile preview

BBT003

Development stage: Preclinical
Lead developer: Bambusa Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

BBT003 is a preclinical-stage biologic drug candidate being developed by Bambusa Therapeutics for the treatment of inflammatory bowel disease. While specific molecular details have not been disclosed, it is part of Bambusa's pipeline focused on next-generation bispecific antibodies and novel biologics targeting immunological and inflammatory diseases. The company describes its pipeline candidates, including BBT003, as having "best-in-disease potential" for their respective indications. As of June 2025, BBT003 remains in preclinical development and has not yet entered clinical trials[1][2][3][4][7].

Beyond the preview

Go deeper on BBT003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BBT003.

Explore the full profile